PHARMACOLOGICAL GUIDE FOR INSOMNIA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper gives the current views of the problem of insomnias, their classification, and basic drug treatments. It emphasizes the role of the objective study of sleep - polysomnography. The administration of hypnotics and the minimized use of benzodiazepines are most important in the pharmacotherapy of insomnia. The authors present the data of foreign and their clinical and polysomnographic studies of the effect of doxylamine (Donormyl) on patients with insomnia. The subjective evaluation of the positive effect of a 10-day course of Donormyl is confirmed by the objective studies of the sleep pattern undergoing positive changes that involve the most important indicators of the sleep pattern (shorter duration of falling asleep; longer rapid eye movement sleep; better sleep quality index). In terms of its high safety and tolerability, Donormyl may be appreciated as an effective agent to treat insomnia.

Full Text

Restricted Access

About the authors

Ya. Levin

I.M. Sechenov First Moscow State Medical University

Email: info@sleepmed.ru
Professor MD

K. Magomedova

I.M. Sechenov First Moscow State Medical University

Email: info@sleepmed.ru
MD

References

  1. Hausser-Hauw et al. Effect on sleep architecture and residual effect of a dose of 15 mg of Doxylamine in healthy volunteers Sep Hop Paris 1995; 71: no 23-24,742-750.
  2. B.SCHADECK, M.CHELLY etal. Comparative efficacy of doxylamine and zolpidem for the treatment of common insomnia. Sep Hop Paris 1996; 72: no 13-14,428-439.
  3. Левин Я.И., Стрыгин К.Н.. Применение Донормила в терапии инсомнии//Лечение нервных болезней. Т.6. 2(16). 2005; 2; с.23-26.
  4. Левин Я.И., Вейн А.М.. Современная сомнология и некоторые аспекты применения снотворных препаратов//Кремлевская медицина. Клинический вестник. Доп. номер, 1998 №5; с.56-59. Данная информация предназначена для врачей. RU.DOX.12.01.01
  5. Вейн А. М. О сне // Журн. Современная психиатрия им. П. Б. Ганнушкина. -1998; 43: 4-6.
  6. Инсомния: современные диагностические и лечебные подходы / под ред. Левина Я. И. - М: Медпрактика-М, 2005. - 115 с.
  7. Левин Я. И., Стрыгин К. Н. Донормил в терапии инсомнии // Лечение нервных болезней. - 2005; № 2 (16).
  8. Левин Я. И. Нарушения сна. В кн: Национальное руководство по неврологии/под ред. Е. И. Гусева, А. Н. Коновалова, В. И. Скворцовой и др. - М.: ГЭОТАР-Медиа, 2009. - С. 548-565.
  9. Левин Я. И. Нейрофизиологические, нейрохимические, вегетативные и хронобиологические аспекты медицины сна // Росс. физиол. журн. им. И. М. Сеченова. - 2011; 97 (4): 388-403.
  10. Левин Я. И. Парадигма медицины сна в современной медицине. Эффективная фармакотерапия // Неврология и психиатрия. - 2011; 2: 14-22.
  11. Ford D., Kamerow D. Epidemiologic study of sleep disturbances and psychiatric disorders: an opportunity for prevention? // JAMA. - 1989; 262: 1479-1484.
  12. Hausser-Hauw et al. Effect on sleep architecture and residual effect of a dose of 15 mg of Doxylamine in healthy volunteers // Sep. Hop. Paris. - 1995; 71: 23-24, 742-750.
  13. ICSD - International Classification of Sleep Disorders. Diagnostic and Coding Manual. Diagnostic Classification Steering Comittee, Thorpy, Michael J. (Editor). - 2005. - 293 p.
  14. Kryger M., Roth T., Dement W. Principles and practice of sleep medicine/(5-th Editon by). - W. B. Saunders Company. - 2011. - 1723 p.
  15. Mendelson W., Gamett D., Linnoila M. Do insomniacs have impaired daytime functioning? // Biol. Psichatricy. - 1984; 19: 1261-1264.
  16. Rechtchaffen A., Kales A. A manual of standardized terminology, techniques and scoring for sleep stages of human subjects. Bethesda, Washington D. C. U. S. Government Printing office, 1968. - 235 p.
  17. Schadeck B., Chelly M. et al. Comparative efficacy of doxylamine and zolpidem for the treatment of common insomnia // Sep. Hop. Paris. - 1996; 72: 13-14, 428-439.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies